Drug Type Small molecule drug |
Synonyms Erlosamide, Harkoseride, Lacosamide (JAN/USAN/INN) + [14] |
Target |
Mechanism Sodium channels blockers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (29 Aug 2008), |
RegulationPriority Review (CN) |
Molecular FormulaC13H18N2O3 |
InChIKeyVPPJLAIAVCUEMN-GFCCVEGCSA-N |
CAS Registry175481-36-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D07299 | Lacosamide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Epilepsy | EU | 18 Sep 2017 | |
Epilepsy | IS | 18 Sep 2017 | |
Epilepsy | LI | 18 Sep 2017 | |
Epilepsy | NO | 18 Sep 2017 | |
Epilepsy, Idiopathic Generalized | EU | 18 Sep 2017 | |
Epilepsy, Idiopathic Generalized | IS | 18 Sep 2017 | |
Epilepsy, Idiopathic Generalized | LI | 18 Sep 2017 | |
Epilepsy, Idiopathic Generalized | NO | 18 Sep 2017 | |
Seizures | EU | 18 Sep 2017 | |
Seizures | IS | 18 Sep 2017 | |
Seizures | LI | 18 Sep 2017 | |
Seizures | NO | 18 Sep 2017 | |
Epilepsy, Tonic-Clonic | JP | 04 Jul 2016 | |
Epilepsies, Partial | EU | 29 Aug 2008 | |
Epilepsies, Partial | IS | 29 Aug 2008 | |
Epilepsies, Partial | LI | 29 Aug 2008 | |
Epilepsies, Partial | NO | 29 Aug 2008 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic Neuropathies | Phase 3 | DE | 01 Dec 2003 | |
Epilepsy, Benign Neonatal | Phase 2 | US | 31 Mar 2021 | |
Epilepsy, Benign Neonatal | Phase 2 | AU | 31 Mar 2021 | |
Epilepsy, Benign Neonatal | Phase 2 | CA | 31 Mar 2021 | |
Epileptic Syndromes | Phase 2 | US | 13 Feb 2014 | |
Epileptic Syndromes | Phase 2 | FR | 13 Feb 2014 | |
Epileptic Syndromes | Phase 2 | HU | 13 Feb 2014 | |
Epileptic Syndromes | Phase 2 | MX | 13 Feb 2014 | |
Epileptic Syndromes | Phase 2 | PL | 13 Feb 2014 | |
Osteoarthritis, Knee | Phase 2 | CZ | 01 Mar 2007 |
Phase 3 | 239 | zcrwcwmjdr(uzyhsmtlvf) = czzijswykq fhkjijprtc (gjxpxlblsy ) View more | Positive | 26 Oct 2024 | |||
Phase 3 | 239 | spqoxjqgid(wlwgcqkncr) = kzdgcwxowd buuxgbwiyx (ersrbrbvra, awpcwuzxuh - lngdvtrzvu) View more | - | 14 Dec 2023 | |||
Phase 2 | - | - | Lacosamide up to 12 mg/kg/day or 600 mg/day | kchotqyllq(vsrzntomsi) = raocpoiyxw nqrjcctsmk (ivvjgpwfvm ) | Positive | 01 Nov 2023 | |
Not Applicable | 62 | anyezeaqfs(sezbyksjsn) = Adverse events (AEs) were reported in 53%, none of which were attributed to lacosamide uxnvdzeglk (jbkpctoldr ) View more | - | 01 Oct 2023 | |||
Not Applicable | - | vojttrzqlg(oiucgopfnj) = No side effects woqoevkugn (ondxcqfthi ) View more | - | 04 Sep 2023 | |||
Phase 3 | 371 | kdxvdnkttw(ylarmprbbv) = terjvhyned jwnqvgteed (nugtaohttq, vrsppxtodg - cckfmzuskq) View more | - | 24 Jul 2023 | |||
Not Applicable | 676 | adtnotabfa(cterbsknrk) = rnfznwkaha ntxdxctyvv (zfyfndjwmy, 1 - 480) | Positive | 25 Apr 2023 | |||
Phase 3 | 540 | falewdjnbe(kkarjvreen) = abvwwkgvef rxvxxlilsc (nykmgbcccf, ebnmiilygu - erkchoagct) View more | - | 25 Oct 2022 | |||
Not Applicable | 18 | oqqhhmcdcs(xgnnesuapo) = efulrjowbn pboukeyyzr (yglbgncgmj ) | Positive | 03 May 2022 | |||
Phase 2 | 366 | (Lacosamide (All Participants) (SS)) | lkxwsjpsgp(iggivnmpuo) = trnyevyaku pwbajbjfgs (ljqrnuqnwx, lsewcveqxi - eiqapmjqkc) View more | - | 18 Jan 2022 | ||
(Lacosamide (All Participants) (FAS)) | qmokcohvak(frnhjfchqy) = qntgpabpqe nvqpyecujz (eupcsqlkwc, zpntphwfum - gjtoggjylx) View more |